Previous 10 | Next 10 |
Marinus Pharmaceuticals (NASDAQ: MRNS ) +61% after ganaxolone successful in pivot study in rare type of epilepsy. More news on: Marinus Pharmaceuticals, Inc., Plus Therapeutics, Inc., Tiziana Life Sciences PLC, Stocks on the move, , Read more ...
Arbutus Biopharma (NASDAQ: ABUS ) jumps 10% premarket on heels of positive data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, a GalNAc delivered RNAi compound. More news on: Arbutus Biopharma Corporation, Healthcare stocks news, Stocks on the move, ...
Mean HBsAg reduction of 1.23 log 10 IU/mL at week 12 with a favorable safety and tolerability profile WARMINSTER, Pa., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developin...
WARMINSTER, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (includi...
Assembly Biosciences (NASDAQ: ASMB ) has announced a clinical collaboration with Arbutus Biopharma (NASDAQ: ABUS ) to evaluate Assembly’s ABI-H0731 in combination with Arbutus’ AB-729 and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) ...
Moxian (NASDAQ: MOXC ) +52% on merger with Btab . More news on: Moxian, Inc., VBI Vaccines Inc., ZAGG Inc, Stocks on the move, , Read more ...
SOUTH SAN FRANCISCO, Calif. and WARMINSTER, Pa., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced that the companies have entered into a clinical collaboration agreement to evaluate Assembly’...
EyeGate Pharmaceuticals (NASDAQ: EYEG ) +35% on development path for conjunctivitis treatment. More news on: EyeGate Pharmaceuticals, Inc., Cellular Biomedicine Group, Inc., Vascular Biogenics Ltd., Stocks on the move, , Read more ...
Shares of Arbutus Biopharma (NASDAQ: ABUS) are down 15% at 2:14 p.m. EDT, following the release of the biotech's first-quarter results, although there didn't appear to be anything in the press release to justify the sell-off. Arbutus is still a clinical-stage biotech, so revenue is minimal ...
Arbutus Biopharma Corporation (ABUS) Q2 2020 Earnings Conference Call August 7, 2020 08:45 a.m. ET Company Representatives Bill Collier - President, Chief Executive Officer Mike Sofia - Chief Scientific Officer Gaston Picchio - Chief Development Officer Dave Hastings - Chief Fi...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...